Elevation Oncology (NASDAQ:ELEV - Get Free Report)'s stock had its "outperform" rating reissued by stock analysts at Wedbush in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $8.00 price objective on the stock. Wedbush's target price points to a potential upside of 116.22% from the stock's current price.
Several other research firms have also issued reports on ELEV. JMP Securities restated a "market outperform" rating and issued a $7.00 price target on shares of Elevation Oncology in a research report on Thursday, March 7th. HC Wainwright restated a "buy" rating and issued a $6.00 target price on shares of Elevation Oncology in a report on Tuesday, April 9th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $7.25.
Get Our Latest Stock Report on ELEV
Elevation Oncology Price Performance
Shares of Elevation Oncology stock traded down $0.12 during trading on Friday, hitting $3.70. The stock had a trading volume of 431,646 shares, compared to its average volume of 2,510,307. The business has a fifty day moving average of $4.36 and a two-hundred day moving average of $2.37. Elevation Oncology has a fifty-two week low of $0.36 and a fifty-two week high of $5.89. The firm has a market cap of $202.17 million, a P/E ratio of -2.55 and a beta of 1.52. The company has a debt-to-equity ratio of 0.55, a current ratio of 21.22 and a quick ratio of 21.22.
Elevation Oncology (NASDAQ:ELEV - Get Free Report) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.02. On average, sell-side analysts expect that Elevation Oncology will post -0.87 earnings per share for the current fiscal year.
About Elevation Oncology
(
Get Free Report)
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Further Reading
Before you consider Elevation Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevation Oncology wasn't on the list.
While Elevation Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
